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Purpose: Repeat radiation therapy (RT) using photons/X-rays for locally recurrent breast cancer results in
increased short and long-term toxicity. Proton beam RT (PBRT) can minimize dose to surrounding organs,
thereby potentially reducing toxicity. Here, we report the toxicity and clinical outcomes for women who
underwent re-irradiation to the chest wall for locally recurrent breast cancer using PBRT.
Materials and methods: This was a retrospective study analyzing 16 consecutive patients between 2013
and 2018 with locally recurrent breast cancer who underwent re-irradiation to the chest wall with
PBRT. For the recurrent disease, patients underwent maximal safe resection, including salvage mastec-
tomy, wide local excision, or biopsy only per surgeons recommendations. Systemic therapy was used
per the recommendation of the medical oncologist. Patients were treated with median dose of 50.4
Cobalt Gray Equivalent (CGyE) in 28 fractions at the time of re-irradiation. Follow-up was calculated from
the start of second RT course. Acute toxicities were defined as those occurring during treatment or up to
8 weeks after treatment. Late toxicities were defined as those occurring more than 8 weeks after the com-
pletion of therapy. Toxicities were based on CTCAE 4.0.
Results: The median age at original diagnosis and at recurrence was 49.8 years and 60.2 years, respec-
tively. The median time between the two RT courses was 10.2 (0.7–20.2) years. The median follow-up
time was 18.7 (2.5–35.2) months. No local failures were observed after re-irradiation. One patient devel-
oped distant metastasis and ultimately died. Grade 3–4 acute skin toxicity was observed in 5 (31.2%)
patients. Four (25%) patients developed chest wall infections during or shortly (2 weeks) after re-
irradiation. Late grade 3–4 fibrosis was observed in only 3 (18.8%) patients. Grade 5 toxicities were not
observed. Hyperpigmentation was seen in 12 (75%) patients. Pneumonitis, telangiectasia, rib fracture,
and lymphedema occurred in 2 (12.5%), 4 (25%), 1 (6.3%), and 1 (6.3%) patients, respectively.
Conclusions: Re-irradiation with PBRT for recurrent breast cancer has acceptable toxicities. There was a
high incidence of acute grade 3–4 skin toxicity and infections, which resolved, however, with skin care
and antibiotics. Longer follow-up is needed to determine long-term clinical outcomes.
 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Breast cancer is one of the most frequently diagnosed cancer in
the world, with approximately 127 new cases per 100,000 persons
each year [1]. Due to the improvement in cancer screening and
treatment, breast cancer mortality has steadily declined over the
last decade [2]. Combined therapy for breast cancer, including
surgery with adjuvant radiation therapy (RT), and appropriate sys-
temic therapy has led to further improvement in post-treatment
morbidity and mortality with local disease recurrence rates
decreasing by 50% with combined therapy [3–5]. Despite these
advances, locally recurrent disease remains an issue for a signifi-
cant number of patients. Local recurrence rates still remain
approximately 10–20% at 10 years, and can be as high as 40%
depending on the stage, histology, estrogen/progesterone (ER/PR)
receptor status, and Her-2 gene amplification [3–6].
Uncontrolled locally recurrent breast cancer, especially those
that occur on the chest wall, can cause significant morbidity such
as ulcerations, bleeding, pain, and an overall decrease in the quality
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of life for these patients. Treatment options for local control of
recurrent disease primarily involves surgery, with adjuvant RT
being used in select cases. While surgery plus RT is effective for
local recurrence, recent research has shown increased late toxici-
ties including cardiotoxicity as a result of re-irradiation [7,8].
Due to the concerns of increased short and long-term toxicity,
especially lung and cardiac toxicity, as a result of the cumulative
RT dose of two RT courses, a second course of RT using X-rays (pho-
tons) for locally recurrent breast cancer has been met with resis-
tance among the radiation oncology community [8]. With the
introduction of proton beam RT (PBRT), there is now a possibility
to reduce the cumulative RT dose to the surrounding normal
organs at risk, including the heart and lung. A study by Tommasino
et al. has suggested that lower radiation doses can be delivered to
cardiac and pulmonary structures with PBRT compared to photon
RT [9]. This reduction in dose to surrounding organs can translate
to reduced toxicity in the short- and long-term. However, there is
currently limited literature describing PRBT for re-treatment of
breast cancer. Here, we report the toxicity and outcomes for
women who underwent re-irradiation to the chest wall for locally
recurrent breast cancer using PBRT.
2. Materials and methods
An IRB approved institutional database was used as a source for
this analysis. All consecutive patients between the year 2013 and
2018 who were diagnosed with recurrent breast cancer, and who
were re-irradiated with PBRT at our institution were identified.
Patients were required to have received previous radiation for ipsi-
lateral breast cancer that overlapped with the current re-
irradiation treatment field. As part of this study, patients were only
included if re-irradiation was delivered using proton beam radia-
tion therapy. As such, patients treated with X-rays (photons) for
re-irradiation were excluded from this analysis. Patients with
metastatic disease or patients treated with the primary goal of pal-
liation were also excluded.
Type of surgery (salvage mastectomy, wide local excision, or
biopsy only) was generally a maximum safe resection per the rec-
ommendation of the surgeon. Similarly, the use of systemic ther-
apy (chemotherapy and/or endocrine therapy) was at the
discretion of the medical oncologist. The median RT dose for the
first course of RT was 50 Gy with a median boost dose of 10 Gy,
and for the second course of treatment, 50.4 Cobalt Gy Equivalent
(CGyE) in 28 fractions. A boost of a median dose of 10 CGyE was
also delivered in 3 patients. Re-irradiation was delivered using pas-
sive scatter proton therapy using Mevion S250 (Mevion Medical
Systems, Littleton, MA, USA). A cumulative dose constraint of max-
imum dose of 66 Gy and V60 < 0.1 cc was used for the brachial
plexus. We did not use a specific dose constraints for the lung,
heart, or the esophagus as proton therapy adds minimal to no dose
to these structures. Concurrent hyperthermia was also utilized for
patients with gross disease and close/positive margins, or skin
involvement using Sonotherm 1000 (Labthermics Technologies,
Inc, Champaign, IL, USA). For hyperthermia, the goal temperature
was 41–43 C for one hour and was delivered weekly within
30 min of RT administration for a total of 6 sessions. For all
patients, temperatures were measured with multisensory thermo-
couple probes on the skin.
Follow up was calculated from the start of second RT course.
Local control, distant control, and overall survival were calculated
from the date of the first fraction of re-irradiation. Local control,
distant control, and overall survival were analyzed using the
Kaplan-Meier method. Toxicities were based on the Common Ter-
minology Criteria for Adverse Events (CTCAE) 4.0. Acute toxicities
were defined as those occurring during treatment or up to 8 weeks
after treatment. Late toxicities were defined as those occurring
more than 8 weeks after the completion of therapy. To avoid bias,
aggravation of pre-existing toxicity as well as toxicity of uncertain
cause were considered to be related to the present treatment and
scored accordingly. Statistical analysis was carried out using SPSS
version 23. The level of statistical significance was considered
<0.05 for all analyses.
3. Results
A total of 16 patients who met the aforementioned inclusion
and exclusion criteria were identified and included for the final
analysis. The median age at the initial diagnosis of breast cancer
was 49.8 years. At the initial diagnosis, 7 patients (43.8%)
Table 1
Clinical characteristics at initial diagnosis.
Patients (n = 16) (%)






















Breast Conserving Surgery 9 (56.2)
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Axillary Lymph Node Dissection 10 (62.5)
Sentinel Lymph Node 5 (31.3)
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underwent mastectomy and 9 patients (56.2%) underwent breast
conserving surgery. Patient characteristics at the time of initial
diagnosis are presented in Table 1. The median age at the time of
the diagnosis of recurrence was 60.2 years. The median time
between the first and the second course of RT was 10.2 years
(0.7–20.2 years). The median tumor size at the time of the recur-
rence was 1.5 cm (range: 0.9–10.0 cm). A total of 3 (18.8%) patients
also had lymph node involvement at the time of recurrence. The
majority of the patients (81.2%) had invasive ductal carcinoma.
Nine patients (56.3%) had tumors positive for ER/PR receptor, three
patients (18.8%) had tumors with Her-2 gene amplification, and
four patients (25%) had triple negative breast cancer. Patient char-
acteristics at the time of recurrence are presented in Table 2.
With regards to the type of surgery for the treatment of their
recurrent disease, 6 patients underwent salvage mastectomy, 8
patients underwent wide local excision, and 2 patients underwent
a biopsy only. The re-irradiation target was the chest wall in 12
(75%) patients, and both chest wall and regional nodes (axillary,
supraclavicular, and internal mammary lymph node chain) in 4
(25%) patients. There were no patients who received repeat regio-
nal nodal irradiation, however, one patient did receive high tan-
gent treatment for the initial treatment who then went on to
receive regional nodal irradiation with protons. The median RT
dose was 50.4 CGyE (41.4–50.4 CGyE). A RT boost of 10–16 Gy
was delivered to 3 (18.8%) patients. For the proton plan, the med-
ian ipsilateral lung V20 was 13% (range 0.2%  26.8%), ipsilateral
mean lung dose was 6.05 Gy (range 0.34–11.7), mean heart dose
was 0.24 Gy (range 0.02–2.13), and mean esophagus dose was
0.0 Gy (range 0.0–10.4). Cumulative dose information was avail-
able for 9 patients. The median mean heart dose was 4.8 Gy, V5
of 19.8%, V10 of 14.9%, and V25 of 5.8%. The median ipsilateral
mean lung dose was 22.8 Gy, V20 of 35.3%, V30 of 27.1%, and
V40 of 21.3%. An example patient’s treatment plan showing the
proton dose distribution and the cumulative dose distribution is
shown in Fig. 1. However, it should be noted that many patients
had significant anatomical changes between the two treatment
courses and as such, the cumulative dose information may not be
accurately represented. Concurrent hyperthermia was utilized in
10 (62.5%) patients. Systemic therapy in the form of chemotherapy
was administered to 4 (25%) patients and endocrine therapy was
administered to 8 (50%) patients.
The median follow up time after the start of the 2nd RT course
was 18.7 months (range: 2.5–35.2 months). There were no local or
regional failures observed after re-irradiation. Only one patient
developed distant metastasis and ultimately died as a result of
her metastatic disease. However, she lived for 15.6 months after
the development of her distant metastases. The 18-month local
control, distant control, and overall survival was 100%, 93.3%, and
88.9% respectively (Fig. 2a–c).
Grade 3–4 acute skin toxicity was observed in 5 (31.2%)
patients. This was mostly in the form of moist desquamation and
ulceration. One patient had a grade 4 ulceration that occurred
during treatment and persisted 24 weeks after treatment. There
Table 2
Clinical characteristics at recurrence.
Patients (n = 16) (%)
Age at Recurrence (Years)
Median (Years) 60.2
Range (Years) 37.5–86.5




Chest Wall Only 9 (56.3)
Breast Only 4 (25.0)
Nodal Only 1 (6.2)
Chest Wall and Nodal 0 (0.0)
Breast and Nodal 2 (12.5)
















Salvage Mastectomy 6 (37.5)
Chest Wall Excision 8 (50.0)





Axillary Lymph Node Dissection 2 (12.5)
Sentinel Lymph Node 3 (18.7)
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were 4 (25%) patients who developed chest wall infections during
or shortly (2 weeks) after re-irradiation. These patients required
antibiotics for treatment of their infections. Late grade 3–4 fibrosis
was observed in only 3 (18.8%) patients. Hyperpigmentation that
persisted through their last follow up was seen in 12 (75%)
patients. Other RT related toxicities such as pneumonitis, telang-
iectasia, rib fracture, and lymphedema occurred in 2 (12.5%), 4
(25%), 1 (6.3%), and 1 (6.3%) patients respectively. The rib fracture
observed in one patient was asymptomatic and was incidentally
found on a CT scan performed as part of her regular follow up.
RT-related pericarditis was not observed in the cohort, nor was
any other cardiotoxicity. Furthermore, no Grade 5 toxicity was
observed in this cohort. For subjective measures, 14 patients
reported a maximum pain score between 0 and 5 (87.5%), while
2 patients reported a score between 6 and 10 (12.5%) during treat-
ment. Toxicity details are presented in Table 3.
Fig. 1. A. Dose colowash showing the patients current re-treatment plan using proton radiaiton therapy. B. Dose colowash showing the patients composite treatment dose
distribution of the current proton plan plus the prior radiation plan. C. Representative dose volume histogram of the proton re-irradiaiton plan. D. Representative dose volume
histogram of the composite treatment plan of the prior photon plan and current proton plan.
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4. Discussion
We retrospectively evaluated the clinical outcomes and toxicity
after re-irradiation of recurrent breast cancer using PBRT. To our
knowledge, this is one of the few reports describing the clinical
outcomes and toxicity of re-irradiation of recurrent breast cancer
using PBRT. In the 16 patients that were treated with PBRT in this
cohort, there were no local recurrences, and only one distant fail-
ure and subsequent death from distant metastasis. We observed
a high rate of acute grade 3–4 skin toxicity, and chest wall infec-
tions. However, they all resolved, with appropriate skin care regi-
mens and antibiotics within 6 weeks after completion of
treatment. More importantly, cardiac toxicity was not observed
in any of the patients and pneumonitis was rarely observed. Over-
all, treatment was effective with the 18-month local control and
distant control rates of 100% and 93.3%, respectively.
Several studies have discussed toxicities and outcomes in
patients who underwent re-irradiation with X-ray/photon radia-
tion after locally recurrent breast cancer [10–14]. In one of the lar-
gest multi-institutional retrospective study by Wahl et al., which
recorded outcomes for breast cancer patients with local recurrence
after re-irradiation with X-rays, a lower percentage of the cohort
experienced acute Grade 3–4 skin toxicities compared to the find-
ings in our study [11]. In a study by Oldenborg et al., the authors
reported on 414 pretreated patients with inoperable locally recur-
rent breast cancer who received re-RT with electrons, photons, or
combination of electron and photon therapy along with hyperther-
mia [14]. Acute grade 3–4 skin toxicity in the form of desquama-
tion and ulceration was noted in 24% of patients, slightly lower
than our findings. However, several studies have shown high rates
of skin toxicity with proton beam therapy, both in the setting of
initial treatment and re-irradiation [15–17]. For example, a study
by Bradley et al. showed 22% rate of grade 3–4 dermatitis, similar
to our findings [18]. Similarly, an abstract published by Niska et al.
on PBRT for locally recurrent breast cancer in patients without
prior RT also showed a 21% rate of acute grade 3+ skin toxicity [19].
Although fewer acute skin toxicities were reported in the study
by Wahl et al. and Oldenborg et al. [11,14] than the findings in the
current study, the acute skin toxicities in our study all resolved
with appropriate skin care and antibiotic treatment with no long
term consequences. A potential reason for high rate of acute grade
3+ skin toxicity in our cohort is that a large proportion of our
patients (62.5%) underwent concurrent hyperthermia, which has
been a well-established radiosensitizer. For example, a study by
Vernon et al. [20] showed improved clinical response and local
control with combined use of RT and hyperthermia in breast can-
cer, however, an increased risk of skin blistering (11% vs. 2%) was
found with the addition of hyperthermia to RT. Additionally, they
also found a 7% rate of ulceration and 7% rate of necrosis with
the use of hyperthermia compared to only 2% and 1% respectively
Fig. 2. A. Local Control. B. Distant Control. C. Overall Survival.
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in the RT-only arm [20]. Despite increased risk of acute toxicities,
PBRT may still be the more efficacious and less detrimental choice
in the long-term as some have claimed that survival can be
improved if deaths secondary to cardiac events could be mitigated
[21].
In regards to late toxicities, a study by Muller et al. [22]
reported moderate incidence of late grade 3 skin toxicity after
re-irradiation of the chest wall in breast cancer patients (20%).
Pneumonitis was also observed in their cohort after re-irradiation
in 10% of patients. Comparatively, we observed a similar rate of
late grade 3–4 skin fibrosis in 3 patients (18.8%) and only 1 patient
developing pneumonitis. Additionally, the more important late
cardiac toxicities were likely not adequately captured in either of
the two studies previously discussed due to the short median fol-
low up of 12 months in Wahl et al. and 41 months in Muller
et al., as well as 18 months in our study. In regards to the clinical
outcomes, the local disease free survival and overall at 1-year in
Wahl et al. was only 66% and 64%, respectively compared to
100% and 88.9% at 18-months, respectively in our study [11]. How-
ever, longer follow-up will be needed to assess late toxicities such
cardiac toxicity of PBRT in this cohort.
One of the clear advantages of PBRT over X-ray/photon therapy
is lower RT dose to the heart, thereby translating into a lower risk
of cardiac toxicity. While we were unable to find any clinical stud-
ies assessing the long term impact of re-irradiation of locally recur-
rent breast cancer using proton beam therapy, there have been a
several dosimetric studies comparing doses delivered to organs
at risk, mainly the heart and the lungs secondary to chest wall irra-
diation using proton versus intensity modulated RT (IMRT) [18,23–
25]. In one of these studies, the left lung and cardiac doses were
reduced by a factor of 2.5 using protons vs. IMRT, and cardiac doses
were reduced by a factor of 20 with protons [24]. In another study,
the mean heart dose was reduced from 16 Gy with IMRT to 6 Gy
with PBRT [23]. Similarly, a study by Bradley et al. showed the
median cardiac V5 of only 0.6% with PBRT compared to 16.3% with
photon based RT [18]. As such, it can be anticipated that at longer
follow up, our study will likely find low rates of cardiac toxicity
beyond the risk that these patients already have from their first
course of irradiation.
Although the study shows promising results, there are a few
limitations to be considered within the study. Firstly, given the ret-
rospective nature of the study, toxicities may not be accurately
captured compared to a prospective or a patient reported out-
comes study. Median follow-up time after re-irradiation in our
study was only 18.7 months, which may have reduced the scope
of late toxicities that were observed in our patients. Even though
cardiac toxicities were not observed in any patients, longer follow
up is needed to conclude about the safety of PBRT as it relates to
the heart. Nonetheless, evidence does suggest that PBRT results
in minimal heart dose, which theoretically improves the cardiac
toxicity profile of re-irradiation [9]. Another limitation is the small
sample size, which reduces the power of this study, and the varia-
tion of combination treatment within the group. Thus, a larger
study with increased cohort population and longer follow-up time,
along with analyses excluding potential covariates would yield
more definitive results.
There are minimal local treatment options for women with
recurrent breast cancer. Often, it is difficult to obtain a negative
margin, and rates of local failure are high without RT. The only
other currently available treatments are systemic therapy, or pal-
liative doses of RT using photons. With the introduction of PBRT,
re-irradiation with a much higher and more definitive dose of RT
is now an option without the additional risk of pulmonary or car-
diac toxicity. In conclusion, re-irradiation with PBRT for recurrent
breast cancer has acceptable toxicities and offers great short-
term clinical outcomes. There is a high incidence of grade 3–4 skin
toxicity and infections, however, these can be effectively treated
with adequate skin care and antibiotics. Further follow up will be
needed to determine long-term clinical outcomes and the effects
of PBRT on cardiac toxicity.
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